Quarterly report pursuant to Section 13 or 15(d)

SEGMENT INFORMATION (Tables)

v3.19.1
SEGMENT INFORMATION (Tables)
3 Months Ended
Jan. 31, 2019
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment [Table Text Block]
 

For the Three Months Ended

January 31,

 
 

2019

 

2018

Net loss:

 

 

 

 

 

Cchek™ cancer detection platform

$

(1,804,354)

 

$

(623,249)

CAR-T therapeutics

 

(2,487,285)

 

 

(1,109,018)

Patent licensing

 

(674,970)

 

 

(133,207)

 Total

$

(4,966,609)

 

$

(1,865,474)

           

Operating costs and expenses excluding non-cash
   share based compensation:

         

Cchek™ cancer detection platform

$

759,534

 

$

525,614

CAR-T therapeutics

 

800,791

   

954,853

Patent licensing

 

673,239

 

 

127,146

Total

$

2,233,564

 

$

1,607,613

 

 

 

 

 

 

Operating costs and expenses excluding non-cash
   share based compensation

$

2,233,564

 

$

1,607,613

Plus non-cash share-based compensation

 

2,750,164

 

 

266,973

Total operating costs and expenses

$

4,983,728

 

$

1,874,586

 

 January 31,

2019

 

  October 31,

2018

   

Total assets:

 

 

 

 

 

Cchek™ cancer detection platform

$

2,943,476

 

$

2,545,803

CAR-T therapeutics

 

3,112,658

 

 

2,157,359

Patent licensing

 

414,215

 

 

1,745,380

Total

$

6,470,349

 

$

6,448,542